Media coverage about TrovaGene (NASDAQ:TROV) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. TrovaGene earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 46.123147323055 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the headlines that may have impacted Accern’s rankings:

TROV has been the subject of several research reports. Maxim Group set a $4.00 target price on TrovaGene and gave the stock a “buy” rating in a research note on Wednesday, October 18th. lowered TrovaGene from a “buy” rating to a “hold” rating in a research note on Wednesday, November 15th.

Shares of TrovaGene (TROV) traded down $0.01 on Wednesday, reaching $0.25. The company’s stock had a trading volume of 1,766,700 shares, compared to its average volume of 627,279. TrovaGene has a 1-year low of $0.24 and a 1-year high of $2.85.

TrovaGene (NASDAQ:TROV) last announced its quarterly earnings data on Thursday, November 9th. The medical research company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%. The firm had revenue of $0.12 million during the quarter.

ILLEGAL ACTIVITY NOTICE: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.thecerbatgem.com/2017/12/20/trovagene-trov-receiving-somewhat-favorable-media-coverage-analysis-shows.html.

About TrovaGene

Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.

Insider Buying and Selling by Quarter for TrovaGene (NASDAQ:TROV)

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.